Roche gets USFDA nod to Tecentriq-Avastin combination to treat liver cancer
Zurich: Swiss drugmaker Roche said on Friday that the U.S. Food and Drug Administration (FDA) approved its immunotherapy Tecentriq in combination with its drug Avastin for the most common kind of liver cancer.
Also Read: Roche Mixes Actemra With Gilead's Remdesivir In New COVID-19 Trial
The Tecentriq-Avastin mix for unresectable or metastatic hepatocellular carcinoma was approved under the FDA's Real-Time Oncology Review pilot and Project Orbis initiative aimed at speedier access for patients, Roche said. The American Cancer Society estimated that more than 42,000 Americans will be diagnosed with liver cancer this year.
Headquarters in Basel, Roche is a multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Read also: Roche mixes Actemra with Gilead's remdesivir in new COVID-19 trial
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.